Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Malan

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
British Journal of Haematology|October 11, 2022
Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study resultsJohnny Mahlangu, Jose Luis Lamas, Juan Cristobal Morales, et al.
Minerva Stomatologica|February 1, 1989
[Nimesulide: multicenter clinical study for evaluation of its therapeutic effect in odontostomatology]G E Solimei, R Malan, M Viti, et al.
Virus Genes|December 25, 2014
First hepatitis B virus full-length genomic study among blood donors from Argentina: unexpected mutations in the circulating subgenotypes' proteinsC M Delfino, C Berini, W Pedrozo, et al.
British Journal of Haematology|August 23, 2022
A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophiliaJohnny N Mahlangu, Jose Luis Lamas, Juan Cristobal Morales, et al.
Journal for Immunotherapy of Cancer|October 17, 2023
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinomaPhilip Clingan, Rahul Ladwa, Daniel Brungs, et al.
Journal of the American Academy of Dermatology|October 7, 2025
Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 yearsEmily S Ruiz, Eva Muñoz-Couselo, Henri Montaudié, et al.
Lancet (London, England)|April 20, 2004
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN StudyF van Leth, P Phanuphak, K Ruxrungtham, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
British Journal of Haematology|October 11, 2022
Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study resultsJohnny Mahlangu, Jose Luis Lamas, Juan Cristobal Morales, et al.
Minerva Stomatologica|February 1, 1989
[Nimesulide: multicenter clinical study for evaluation of its therapeutic effect in odontostomatology]G E Solimei, R Malan, M Viti, et al.
Virus Genes|December 25, 2014
First hepatitis B virus full-length genomic study among blood donors from Argentina: unexpected mutations in the circulating subgenotypes' proteinsC M Delfino, C Berini, W Pedrozo, et al.
British Journal of Haematology|August 23, 2022
A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophiliaJohnny N Mahlangu, Jose Luis Lamas, Juan Cristobal Morales, et al.
Journal for Immunotherapy of Cancer|October 17, 2023
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinomaPhilip Clingan, Rahul Ladwa, Daniel Brungs, et al.
Journal of the American Academy of Dermatology|October 7, 2025
Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 yearsEmily S Ruiz, Eva Muñoz-Couselo, Henri Montaudié, et al.
Lancet (London, England)|April 20, 2004
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN StudyF van Leth, P Phanuphak, K Ruxrungtham, et al.
Pageof 2